At these dosages, both CLO and TIC decreased atherosclerosis compared to no treatment (CTL) (Fig 2A & 2B) by blocking platelet activity and also by decreasing serum cholesterol levels (Fig 1H)—potentially through suppression of hepatic EGR1 expression (S5A–S5E Fig)—in Ldlr-/-Apobec1-/- hypercholesterolemic mice. The gene discussed is APOBEC1; the disease is atherosclerosis.